Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
proven-effective therapies to people affected by neurological and psychiatric disorders, today announced the appointment of Dr. Deborah Dunsire as a new member and the new chair of the company's board of directors. "We are very excited to welcome Dr. Dunsire to the Neurvati board of directors. She is a renowned industry veteran with a proven track record of success in leading the development and management of neuroscience companies, most recently as CEO of H. Lundbeck A/S where she led the company through a period of significant growth," said Bruce Leuchter , M.D., president and chief executive officer of Neurvati. "As we plan for several important milestones in both our clinical development programs and our business strategy, her insights and global reach within the neuroscience community will play a central role in helping us continue our progress and achieve new levels of momentum. We very much look forward to working with her." From 2018 until her retirement in 2023, Dr. Dunsi
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround [Yahoo! Finance]Yahoo! Finance
- Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal CancerBusiness Wire
- TAK or CTLT: Which Is the Better Value Stock Right Now? [Yahoo! Finance]Yahoo! Finance
- Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 4/25/24 - Form SD
- 4/19/24 - Form 6-K
- 4/15/24 - Form 6-K
- TAK's page on the SEC website